Kanjinti vs. Enhertu: Comparison
Are Kanjinti and Enhertu the Same Thing?
Kanjinti (trastuzumab-anns) and Enhertu (fam-trastuzumab deruxtecan-nxki) are used to treat HER2-positive breast cancer.
Kanjinti is also used to treat HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Both Kanjinti and Enhertu contain a HER2/neu receptor antagonist. Enhertu also contains a topoisomerase inhibitor conjugate.
Side effects of Kanjinti and Enhertu that are similar include headache, diarrhea, nausea, cough, rash, low white blood cell count (neutropenia, leukopenia), fatigue, anemia, inflammation of the mouth and lips, upper respiratory tract infections, and low blood platelets (thrombocytopenia).
Side effects of Kanjinti that are different from Enhertu include chills, fever, infection, congestive heart failure, insomnia, weight loss, mucosal inflammation, runny or stuffy nose, and changes in taste.
Side effects of Enhertu that are different from Kanjinti include vomiting, hair loss, constipation, decreased appetite, abdominal pain, indigestion/heartburn, low potassium (hypokalemia), shortness of breath, nosebleed, interstitial lung disease, dizziness, increased aspartate aminotransferase, increased alanine aminotransferase, and dry eye.
Kanjinti may interact with anthracycline.
Enhertu may interact with other drugs.
What Are Possible Side Effects of Kanjinti?
Side effects of Kanjinti include:
- headache,
- diarrhea,
- nausea,
- chills,
- fever,
- infection,
- congestive heart failure,
- insomnia,
- cough,
- rash,
- low white blood cell count (neutropenia),
- fatigue,
- anemia,
- inflammation of the mouth and lips,
- weight loss,
- upper respiratory tract infections,
- low blood platelets (thrombocytopenia),
- mucosal inflammation,
- runny or stuffy nose,
- changes in taste
This is not a complete list of side effects, and others may occur.
What Are Possible Side Effects of Enhertu?
Common side effects of Enhertu include:
- nausea,
- vomiting,
- fatigue,
- hair loss,
- constipation,
- decreased appetite,
- anemia,
- low white blood cell count (neutropenia, leukopenia),
- diarrhea,
- cough, and
- low platelets (thrombocytopenia),
- abdominal pain,
- inflammation of the mouth and lips,
- indigestion/heartburn,
- rash,
- low potassium (hypokalemia),
- shortness of breath,
- nosebleed,
- interstitial lung disease,
- headache,
- dizziness,
- upper respiratory tract infection,
- increased aspartate aminotransferase,
- alanine aminotransferase, and
- dry eye
What is Kanjinti?
Kanjinti (trastuzumab-anns) is a HER2/neu receptor antagonist indicated for the treatment of HER2 overexpressing breast cancer and the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
What is Enhertu?
Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody and topoisomerase inhibitor conjugate used to treat adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
What Drugs Interact With Kanjinti?
Kanjinti may interact with anthracycline. Tell your doctor all medications and supplements you use. Kanjinti is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Kanjinti and for 7 months following the last dose. It is unknown if Kanjinti passes into breast milk or how it would affect a nursing infant. Consult your doctor before breastfeeding.
What Drugs Interact With Enhertu?
Enhertu may interact with other medicines.
What Drugs Interact With Enhertu?
Enhertu may interact with other medicines.
Tell your doctor all medications and supplements you use.
How Should Kanjinti be Taken?
The dose and regimen of Kanjinti depends on the condition being treated.
How Should Enhertu be Taken?
The recommended dosage of Enhertu is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.